Navigation Links
Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting

r of the UCLA Hepatology Clinical Research Center, will present "Telbivudine Globe Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Steven Han will also present "Hepatitis B Patient Survey: Disease Understanding and Compliance in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Natalie Bzowej, Director of Clinical Hepatology Research at California Pacific Medical Center, will present "A Randomized Trial of Telbivudine vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Elizabeth J. Heathcote, Professor of Medicine at the University of Toronto Western Hospital, will present "Salvage Therapy with Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients from the GLOBE Study" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Yuming Wang, Professor of Infectious Disease, Southwest Hospital, Chongqing, China, will present "A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients with Chronic Hepatitis B: Two- Year Results" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Vinod Rustgi, Co-Director of the Transplant Institute at Georgetown University School of Medicine and Clinical Professor of Medicine at the Medical College of Virginia, will present "A Survey of Hepatitis B Patient Demographics, Disease Characteristics and Management Practice in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Xiao-Jian Zhou, Director, Clinical Pharmacology at Idenix Pharmaceuticals, will present "Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Tenofovir" in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... Pinnacle hip replacement lawsuit ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) now ... of Texas has moved into its third week, ... this week’s witnesses included a DePuy Orthopaedics vice ... performed on the metal-on-metal Pinnacle hip. * (Herlihy-Paoli ...
(Date:9/16/2014)... School of Medicine have launched a phase 1 human ... a new monoclonal antibody for patients with chronic lymphocytic ... in adults. , The new antibody targets ... development and exploited by cancer cells to promote tumor ... of all cancer-related deaths. , Because ROR1 ...
(Date:9/16/2014)... 16, 2014 RxAnte, the leading ... and targeted clinical programs, today announced key changes ... the Company’s drive to improve medication effectiveness through ... programs. On September 2, 2014, Brock Hardaway, chief ... announced that RxAnte founder and President Josh Benner ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Former Major ... today after undergoing successful heart transplantation surgery at Allegheny ... Tekulve, who spent most of his 16-year baseball career ... as a commentator for Root Sports Pittsburgh, was discharged ... surgeon, Stephen Bailey, MD, surgical director of AGH’s heart ...
(Date:9/16/2014)... no longer be used to ascertain the eventual scale ... University of Warwick. , Dr Thomas House, of the ... data from past outbreaks that successfully replicated their eventual ... Ebola Outbreaks and published by eLife , shows ... 2014 outbreak to the model that it is, according ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Latest Testimony in Federal Pinnacle Hip Replacement Trial 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Latest Testimony in Federal Pinnacle Hip Replacement Trial 3Health News:Novel drug targeting leukemia cells enters clinical trial 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2
... of the outcomes of medical tests whose results are ... is common and can lead to serious medical errors ... by researchers from the Regenstrief Institute and the Indiana ... summaries are grossly inadequate at documenting both tests with ...
... - Hard to Treat Diseases, Inc. (HTDS:PK), ( http://www.htdsmedical.com ... (Mellow Hope) announced today that the general manager of ... to a significant new business development opportunity related to ... to participate in a formal tender process to supply ...
... , JEDDAH, Saudi Arabia, Aug. 7 ... about themselves, and Saudi women are no exception. But is ... strong guiding force in the kingdom? Read about how plastic ... , http://susiesbigadventure.blogspot.com/2009/08/plastic-surgery-in-saudi-arabia.html , ...
... if fall outbreak proves more severe, government says , ... that swept across the United States last spring during ... repeated this fall, according to new guidelines issued Friday ... noted that everything could change if the outbreak suddenly ...
... Aug. 7 Pharmaceutical Institute, a leading provider of specialized ... that Garry O,Grady has been appointed Senior Vice President and ... Mr. O,Grady will manage the day-to-day operations of the business, ... and sales teams. , , Mr. O,Grady ...
... , , NEW YORK, Aug. 7 ... need additional vaccines beyond those received when they were infants or ... (CDC) estimates, most pre-teens and teens do not have all the ... risks for certain diseases and protection from some childhood vaccines can ...
Cached Medicine News:Health News:Fumbled handoffs can lead to medical errors 2Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 2Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 3Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 4Health News:School Closures May Not Be Necessary When Swine Flu Strikes 2Health News:School Closures May Not Be Necessary When Swine Flu Strikes 3Health News:School Closures May Not Be Necessary When Swine Flu Strikes 4Health News:Garry O'Grady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 2Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 2Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 3
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
... first time in the world, there is a ... to diagnose VVC in female patients. CanDia5® is ... detect the Candida antigens almost instantaneously (within 5 ... blood. There is no similar POC product for ...
... test for Candida albicans in only ... utilizes two enzyme color reactions to ... to read. AlbiQuicktm is performed on ... wells. Incubation time is only five ...
Medicine Products: